Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy targets hard-to-treat melanoma in early trial

NCT ID NCT06540391

Ongoing Disease control Sponsor: Microbiotica Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether adding an experimental treatment (MB097) to the immunotherapy drug pembrolizumab is safe and shows signs of working in people with advanced melanoma that did not respond to standard anti-PD1 therapy. About 41 participants will receive the combination. The main goal is to check for side effects, while also looking for tumor shrinkage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

  • AP-HM - Hopital de la Timone

    Marseille, France

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • CHU de Lille - Hopital Claude Huriez

    Lille, France

  • Centre Georges Francois Leclerc

    Dijon, France

  • Centre Leon Berard

    Lyon, France

  • Consorcio Hospital General Universitario de Valencia

    Valencia, Spain

  • Freeman Hospital

    Newcastle, United Kingdom

  • HCL Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Istituto Clinico Humanitas

    Rozzano, Italy

  • Istituto Europeo di Oncologia

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

    Naples, Italy

  • Royal Marsden Hospital - Surrey

    Sutton, United Kingdom

  • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC

    Madrid, Spain

  • Sussex Cancer Centre

    Brighton, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • The Royal Marsden NHS Foundation Trust

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.